Conference call to discuss to the results on Plozasiran PALISADE to be held on September 3 at 8 am.Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead presents new pivotal Phase 3 data from PALISADE study of Plozasiran
- Arrowhead to advance two RNAi-based obesity candidates into clinical studies
- Arrowhead price target lowered to $28 from $31 at Goldman Sachs
- Arrowhead reports Q3 EPS ($1.38), consensus (55c)
- Arrowhead announces $500M strategic financing with Sixth Street
Questions or Comments about the article? Write to editor@tipranks.com